Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV D46cpΔM2-2 Vaccine in Children
NCT02601612Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2015
- Primary completion
- Apr 2018
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSV LID cp ΔM2-2 in respiratory syncytial virus infection (RSV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of vaccine-related solicited adverse events, Severity of vaccine-related solicited adverse events and 3 more. Started Oct 2015; status: completed.
02
Drugs
RSV LID cp ΔM2-2
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02601612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601612.